Dtsch Med Wochenschr 2009; 134(15): 769-772
DOI: 10.1055/s-0029-1220229
Kommentar | Commentary
Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Myokardbiopsie bei Kardiomyopathie: Wann und warum?

Endomyocardial biopsy in cardiomyopathy: when and why?H.-P Schultheiss1 , U. Kühl1
  • 1Medizinische Klinik II, Kardiologie und Pneumonologie, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin
Further Information

Publication History

eingereicht: 13.1.2009

akzeptiert: 12.2.2009

Publication Date:
01 April 2009 (online)

Literatur

  • 1 Angelini A, Calzolari V, Calabrese F. Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis.  Heart. 2000;  84 245-50
  • 2 Caforio A L, Calabrese F. et al . A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis.  Eur Heart J. 2007;  28 1326-33
  • 3 Cooper L T, Baughman K L, Feldman A M. et al . The role of endomyocardial biopsy in the management of cardiovascular disease.  Eur Heart J. 2007;  28 3076-93
  • 4 Felker G M, Hu W, Hare J M. et al . The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients.  Medicine (Baltimore). 1999;  78 270-83
  • 5 Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders.  Circulation. 2003;  107 857-63
  • 6 Frustaci A. et al .Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy. Eur Heart J 2008: Abstract
  • 7 Holzmann M, Nicko A, Kühl U. et al . Complication rate of right ventricular endomyocardial biopsy via the femoral approach.  Circulation. 2008;  118 1722-1728
  • 8 Kühl U, Pauschinger M, Schwimmbeck P L, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss H P. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction.  Circulation. 2003;  107 2793-8
  • 9 Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss H P. Viral persistence in the myocardium is associated with progressive cardiac dysfunction.  Circulation. 2005;  112 1965-70
  • 10 Liu P P, Schultheiss H P. Myocarditis.  In: Ed by Baunwald Heart Disease, 8 ed. Philadelphia; Saunders 2008: 1775-1792
  • 11 Mangnani J W, Suk Danik H J, Dec G W, DiSalvo T G. Survival in biopsy-proven myocarditis.   Am Heart J. 2006;  151 463-470
  • 12 Schultheiss H P, Kuhl U. [State of diagnostics and therapy of inflammatory cardiomyopathie].   Internist (Berl). 2008;  49 7-16
  • 13 Schultheiss H P, Piper C. et al .The effect of subcutaneous treatment with interferon-beta-1b over 24 weeks on safety, virus elimination and clinical outcome in patients with chronic viral cardiomyopathy. Circulation 2008; 118: Abstract 3322
  • 14 Wojnicz R, Nowalany-Kozielska E, Wojciechowska C. et al . Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy.  Circulation. 2001;  104 39-45

Dr. Uwe Kühl

Medizinische Klinik II, Cardiology und Pneumonology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin

Hindenburgdamm 30

12200 Berlin

Phone: 030/8445-4219

Fax: 030/8445-4219

Email: uwe.kuehl@charite.de